Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tozorakimab in symptomatic COPD with history of exacerbations and elevated eosinophils (COMETA)
NCT06897748Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2025
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tozorakimab in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Started Apr 2025; status: completed.
02
Drugs
tozorakimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06897748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06897748.